



PATENT
Customer No. 22,852
Attorney Docket No.: 06267.0053

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Ilkka LARMA et al.)
Application No.: 09/673,794)
§ 371 Filing Date: December 20, 2000)

Examiner: R. Joynes

Art Unit: 1615

RECEIVED

NOV 06 2003

TECH CENTER 1600/2900

For: CONTROLLED RELEASE PERORAL COMPOSITIONS OF LEVOSIMENDAN

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Response Under 37 C.F.R. § 1.116

This communication responds to the non-Final Office Action dated June 4, 2003. The period for response has been extended by two months to November 4, 2003, by the enclosed Petition for Extension of Time and corresponding fee. Please reconsider this application in view of the following remarks.

Remarks

I. Obviousness-type double patenting rejection

Claims 1-17 are pending in this application. Claims 1-4, 11 and 15-16 were rejected under the judicially created doctrine of obviousness-type double patenting over claims 1-9 of U.S. Patent No. 6,531,458. To expedite prosecution, applicants enclose a Terminal Disclaimer that should avoid the rejection. The filing of the Terminal Disclaimer does not constitute an admission of the propriety of the rejection. See MPEP § 804.02.